Shopping Cart
- Remove All
- Your shopping cart is currently empty
ORIC-944 TFA is a selective, orally active conformational inhibitor that targets the EED subunit of polycomb repressive complex 2 (PRC2). It demonstrates synergistic effects when used in conjunction with androgen receptor pathway inhibitors (ARPI) in the study of metastatic prostate cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | ORIC-944 TFA is a selective, orally active conformational inhibitor that targets the EED subunit of polycomb repressive complex 2 (PRC2). It demonstrates synergistic effects when used in conjunction with androgen receptor pathway inhibitors (ARPI) in the study of metastatic prostate cancer. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.